Page last updated: 2024-11-07

dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate: stable deriv of nifedipine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128753
CHEMBL ID1573
CHEBI ID168902
SCHEMBL ID744307
MeSH IDM0110285

Synonyms (46)

Synonym
67035-22-7
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate
dehydronifedipine
CHEBI:168902
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid, 3,5-dimethyl ester
nifedipine m (dehydro)
NCGC00165922-01
ddnpc
FT-0665630
FT-0665629
AKOS001275336
4-(2-nitrophenyl)-2,6-dimethylpyridine-3,5-dicarboxylic acid dimethyl ester
F3282-0013
dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate
3,5-pyridinedicarboxylic acid, 2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester
b 4759
4-(2'-nitrophenyl)-2,6-dimethylpyridine-3,5-dicarboxylic acid dimethyl ester
2,6-dimethyl-4-(ortho-nitrophenyl)-3,5-pyridinedicarboxylic aciddimenthyl ester
unii-or3w8gt1c8
4-(2-nitrophenyl)-3,5-bis(carboxymethyl)-2,6-dimethylpyridine
or3w8gt1c8 ,
dehydro nifedipine
CHEMBL1573
SCHEMBL744307
2,6-dimethyl-4-(2-nitrophenyl) pyridine-3,5-dicarboxylic acid 3,5-dimethyl ester
DTXSID9052347
mfcd00153847
STL450973
VU0608637-1
F19278
nifedipine impurity a, european pharmacopoeia (ep) reference standard
3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate
nifedipine imp. a (ep); nifedipine nitrophenylpyridine analog; dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate; nitrophenylpyridine analogue of nifedipine; nifedipine impurity a
bay-b 4759
nifedipine minor degradant
3,5-pyridinedicarboxylic acid, 2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester
nifedipine impurity a [ep impurity]
Q63395257
SB38224
dehydronifedipine 100 microg/ml in acetonitrile
AS-79300
SY268246
3,5-pyridinedicarboxylic acid, 2,6-dimethyl-4-(2-nitrophenyl)-,3,5-dimethyl ester
EN300-6743229
AKOS040755399
Z208191950

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters of nifedipine and dehydronifedipine were determined after oral and intravenous administrations of nifedipine to rats in the presence and absence of pioglitazone (0."( Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
Choi, DH; Choi, I; Choi, JS, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Consequently, the absolute bioavailability (AB) of nifedipine in the presence of pioglitazone (1."( Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
Choi, DH; Choi, I; Choi, JS, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylpyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID680052TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM, Oxidized nifedipine: 50 uM) in MDR1-expressing LLC-PK1 cells2001European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb, Volume: 12, Issue:4
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
AID679613TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 uM, Oxidized nifedipine: 50 uM) in MDR1-expressing LLC-PK1 cells2001European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Feb, Volume: 12, Issue:4
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]